{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"Radiologic response by RECIST criteria will be compared between baseline and at 2 months. Disease assessment: Two objective status determinations of CR before progression are required for a best response of CR. Two determinations of PR or better before progression, but not qualifying for a CR, are required for a best response of PR. Two determinations of stable/no response or better before progression, but not qualifying as CR or PR are required for a best response of stable/no response.","groups":[{"description":"The study drugs will be administered in the following manner: Gemcitabine, at 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin, at 100 mg/m² IV infusion over 2 hours.","id":"OG000","title":"Oxaliplatin and Gemcitabine"}],"paramType":"NUMBER","populationDescription":"intention to treat principle","reportingStatus":"POSTED","timeFrame":"Two months","title":"Best Response","type":"PRIMARY","unitOfMeasure":"participants"}